Immix Biopharma will present at the J.P. Morgan Healthcare Conference, showcasing its advances in AL Amyloidosis treatment.
Quiver AI Summary
Immix Biopharma, Inc. announced its participation in the 45th Annual J.P. Morgan Healthcare Conference scheduled for January 11-14, 2027, in San Francisco. The company is a leader in AL Amyloidosis, a severe disease caused by toxic light chains from the immune system leading to organ failure. ImmixBio's flagship treatment, NXC-201, is a CAR-T cell therapy targeting this condition and is currently being evaluated in a multi-center study for relapsed/refractory AL Amyloidosis. NXC-201 has received Breakthrough Therapy Designation and other significant designations from the FDA and EMA, highlighting its potential in treating this devastating illness. A replay of the presentation will be available on their website.
Potential Positives
- Immix Biopharma will present at the prestigious 45th Annual J.P. Morgan Healthcare Conference, enhancing its visibility and credibility in the healthcare sector.
- The company is recognized as a global leader in AL Amyloidosis, which underscores its significant expertise and focus in this specialized area of healthcare.
- ImmixBio's lead candidate, NXC-201, has received multiple designations from the FDA, including Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy, indicating its potential for effective treatment and regulatory support.
- NXC-201 is currently being evaluated in a potentially registrational study, suggesting progress towards market approval and commercial potential.
Potential Negatives
- None
FAQ
What is Immix Biopharma known for?
Immix Biopharma is a global leader in AL Amyloidosis, focusing on innovative therapies for this devastating disease.
When will ImmixBio present at the J.P. Morgan Healthcare Conference?
Immix Biopharma will present at the 45th Annual J.P. Morgan Healthcare Conference from January 11-14, 2027.
What is NXC-201?
NXC-201 is ImmixBio's lead candidate, a CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis.
What designations has NXC-201 received?
NXC-201 has received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy, and Orphan Drug Designation from regulatory agencies.
How can I access the presentation replay?
A link to access the replay will be posted on the Immix website under the Presentation & Events page in the Investors section.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMMX Hedge Fund Activity
We have seen 72 institutional investors add shares of $IMMX stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 2,775,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $28,610,250
- BLACKROCK, INC. added 2,521,595 shares (+538.4%) to their portfolio in Q2 2026, for an estimated $25,997,644
- OPALEYE MANAGEMENT INC. added 2,345,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $24,176,950
- UBS GROUP AG added 1,864,985 shares (+2427.4%) to their portfolio in Q2 2026, for an estimated $19,227,995
- WELLINGTON MANAGEMENT GROUP LLP added 1,473,409 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,190,846
- EVENTIDE ASSET MANAGEMENT, LLC added 1,342,000 shares (+52.6%) to their portfolio in Q2 2026, for an estimated $13,836,020
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,324,918 shares (+319.3%) to their portfolio in Q2 2026, for an estimated $13,659,904
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$IMMX Price Targets
Multiple analysts have issued price targets for $IMMX recently. We have seen 3 analysts offer price targets for $IMMX in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Tazeen Ahmad from B of A Securities set a target price of $27.0 on 06/18/2026
- An analyst from LifeSci Capital set a target price of $19.0 on 06/17/2026
- Robert Burns from HC Wainwright & Co. set a target price of $20.0 on 05/22/2026
Full Release
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.
A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts
Mike Moyer
LifeSci Advisors
[email protected]
Company Contact
[email protected]
